Bristol Myers Squibb (CELG-RI) Current Deferred Tax Assets (2009 - 2015)

Bristol Myers Squibb (CELG-RI) posted quarterly Current Deferred Tax Assets of $1.7 billion for Q3 2015, up 14.64% YoY from $1.5 billion in Q3 2014, and down 8.51% sequentially from $1.9 billion in Q2 2015.

Bristol Myers Squibb (CELG-RI) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends

Bristol Myers Squibb has disclosed Current Deferred Tax Assets across 7 years of filings, most recently posting $1.7 billion for Q3 2015.

  • In Q3 2015, Current Deferred Tax Assets rose 14.64% year-over-year to $1.7 billion; the TTM figure through Sep 2015 stood at $1.7 billion (up 14.64% YoY), while the FY2014 annual figure was $1.6 billion, down 3.35% from the prior year.
  • Current Deferred Tax Assets slipped to $1.7 billion in Q3 2015, from $1.9 billion in the prior quarter.
  • Over the last five years, Current Deferred Tax Assets for CELG-RI reached as high as $2.0 billion in Q3 2013 and fell as low as $1.1 billion in Q2 2011.
  • The 5-year median for Current Deferred Tax Assets is $1.5 billion (2014), against an average of $1.5 billion.
  • Annual changes were most pronounced in 2013 — Current Deferred Tax Assets jumped 66.81% — and 2014, when it plunged 30.82%.
  • A 5-year view of Current Deferred Tax Assets shows it stood at $1.2 billion in 2011, then surged by 33.08% to $1.6 billion in 2012, then rose by 6.51% to $1.7 billion in 2013, then decreased by 3.35% to $1.6 billion in 2014, then rose by 5.29% to $1.7 billion in 2015.
  • According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $1.7 billion, $1.9 billion, and $1.9 billion for Q3 2015, Q2 2015, and Q1 2015 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Sep 30, 2015 1.73 Bn
Sep 30, 2015 1.73 Bn
Jun 30, 2015 1.89 Bn
Jun 30, 2015 1.89 Bn
Mar 31, 2015 1.89 Bn
Mar 31, 2015 1.89 Bn
Dec 31, 2014 1.64 Bn
Dec 31, 2014 1.64 Bn
Sep 30, 2014 1.51 Bn
Sep 30, 2014 1.51 Bn
Jun 30, 2014 1.36 Bn
Jun 30, 2014 1.36 Bn
Mar 31, 2014 1.39 Bn
Mar 31, 2014 1.39 Bn
Dec 31, 2013 1.70 Bn
Dec 31, 2013 1.70 Bn
Sep 30, 2013 2.04 Bn
Sep 30, 2013 2.04 Bn
Jun 30, 2013 1.96 Bn
Jun 30, 2013 1.96 Bn